It is essential for JAK2 inhibitors to not only show potent enzymatic inhibition, but selectivity toward JAK2 to prevent off target side effects, such as peripheral neuropathy, anemia, and thrombocytopenia (Zhao et al., 2016). Here, JAK2 is linked to anemia.